C型肝炎治療薬市場：薬剤クラス別、投与経路別、流通チャネル別、地域別

C型肝炎治療薬の世界市場は、2025年には98億6,000万米ドルと推定され、2032年には132億4,000万米ドルに達すると予測され、2025年から2032年にかけてCAGR4.3％で成長すると予測されます。

図.C型肝炎治療薬市場シェア（%）、2025年地域別

C型肝炎は、重篤な肝障害を引き起こす肝臓感染症です。C型肝炎ウイルスによって引き起こされます。米国では約240万人が罹患しています。しかし、C型肝炎はほとんど症状を起こさないため、そのほとんどは自覚症状がありません。ウイルスは感染者の血液や体液を介して広がります。

C型肝炎のステージ潜伏期。これは最初の暴露から発病までの期間です。潜伏期間は14～80日ですが、平均は45日です。C型急性肝炎：ウイルスが体内に入ってから6ヵ月間続く短期間の病気です。その後、一部の人は自力でウイルスを駆除することができます。C型慢性肝炎C型肝炎にかかるほとんどの人（85％まで）は、病気が長く続く段階（6ヵ月以上）に移行します。これはC型慢性肝炎感染と呼ばれ、肝臓がんや肝硬変のような深刻な健康問題につながる可能性があります。肝硬変。この病気は炎症を引き起こし、時間の経過とともに健康な肝細胞が瘢痕組織に置き換わります。アルコールを飲んだり、HIVに感染したりすると、より早く肝硬変になることもありますが、通常、肝硬変になるまでには約20～30年かかります。

市場力学：

C型肝炎の世界の有病率の増加は、予測期間中の市場成長を助長すると予想されます。例えば、2021年9月18日にNational Center for Biotechnology Informationが発表したデータによると、インドにおけるHCVの有病率は0.5%で、約470万人から1,090万人が罹患しています。

第1章 調査の目的と前提条件

• 調査目的
• 前提条件
• 略語

第2章 市場の展望

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
• Coherent Opportunity Map（COM）

第3章 市場力学、規制、動向分析

• 市場力学
  • 促進要因
• 世界中でC型肝炎の蔓延が増加
• 政府の取り組みの強化
  • 抑制要因
• 副作用の増加
  • 機会
• さまざまな地域での製品の入手可能性の向上
• 影響分析
• 主なハイライト
• 規制シナリオ
• 製品の発売/承認
• PEST分析
• PORTERの分析
• 合併と買収のシナリオ

第4章 C型肝炎治療薬市場- コロナウイルス（COVID-19）パンデミックの影響

• COVID-19疫学
• 供給側と需要側の分析
• 経済への影響

第5章 C型肝炎治療薬市場、薬剤クラス別、2020年～2032年

• NS3/4Aプロテアーゼ阻害剤
• NS5A阻害剤
• NS5Bポリメラーゼ阻害剤
• 併用薬
• その他

第6章 C型肝炎治療薬市場、投与経路別、2020年～2032年

• 経口薬
• 静脈内
• その他

第7章 C型肝炎治療薬市場、流通チャネル別、2020年～2032年

• 病院薬局
• 小売薬局
• オンライン薬局

第8章 C型肝炎治療薬市場、地域別、2020年～2032年

• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東
• アフリカ

第9章 競合情勢

• Gilead Sciences
• AbbVie
• Merck & Co
• Bristol-Myers Squibb
• Johnson & Johnson
• Hoffmann-La Roche AG
• Boehringer Ingelheim
• Achillion Pharmaceuticals

第10章 セクション

• 調査手法
• 出版社について

Global Hepatitis C Drugs Market is estimated to be valued at USD 9.86 Bn in 2025 and is expected to reach USD 13.24 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.3% from 2025 to 2032.

Figure. Hepatitis C Drugs Market Share (%), By Region 2025

Hepatitis C is a liver infection that can lead to serious liver damage. It's caused by the hepatitis C virus. About 2.4 million people in the U.S. have the disease. But it causes few symptoms, so most of them don't know. The virus spreads through an infected person's blood or body fluids.

Stages of Hepatitis C: Incubation period. This is the time between first exposures to the start of the disease. It can last anywhere from 14 to 80 days, but the average is 45. Acute hepatitis C. This is a short-term illness that lasts for the first 6 months after the virus enters your body. After that, some people who have it will get rid of, or clear, the virus on their own. Chronic hepatitis C. For most people who get hepatitis C - up to 85% - the illness moves into a long-lasting stage (longer than 6 months). This is called a chronic hepatitis C infection and can lead to serious health problems like liver cancer or cirrhosis. Cirrhosis. This disease leads to inflammation that, over time, replaces your healthy liver cells with scar tissue. It usually takes about 20 to 30 years for this to happen, though it can be faster if you drink alcohol or have HIV.

Market Dynamics:

The increasing prevalence of hepatitis C globally is expected to aid in the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information on September 18, 2021, the prevalence rate of HCV in India is 0.5%, affecting about 4.7 to 10.9 million people.

Hepatitis C Drugs Market Segmentation:

• By Drug Class
  • NS3/4A Protease Inhibitors
  • NS5A Inhibitors
  • NS5B Polymerase Inhibitors
  • Combination Drugs
  • Others
• By Route of Administration
  • Oral Drugs
  • Intravenous
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • Gilead Sciences
  • AbbVie
  • Merck & Co
  • Bristol-Myers Squibb
  • Johnson & Johnson
  • Hoffmann-La Roche AG
  • Boehringer Ingelheim
  • Achillion Pharmaceuticals

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
• Growing Prevalence of Hepatitis C Globally
• Increasing Government Initiatives
  • Restraints
• Increasing Adverse Effects
  • Opportunities
• Increasing Product Availability in Various Regions
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Hepatitis C Drugs Market- Impact of Coronavirus (COVID-19) Pandemic

• COVID-19 Epidemiology
• Supply Side and Demand Side Analysis
• Economic Impact

5. Hepatitis C Drugs Market, By Drug Class, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• NS3/4A Protease Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• NS5A Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• NS5B Polymerase Inhibitors
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Combination Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)

6. Hepatitis C Drugs Market, By Route of Administration, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Oral Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Intravenous
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

7. Hepatitis C Drugs Market, By Distribution Channel, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, 2025and 2032 (%)
  • Y-o-Y Growth Analysis, 2021- 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)

8. Hepatitis C Drugs Market, By Region, 2020-2032, (US$ Bn)

• Introduction
  • Market Share Analysis, By Country, 2025and 2032 (%)
  • Y-o-Y Growth Analysis, For Country 2021-2032
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • China
    • Japan
    • India
    • Australia
    • ASEAN
    • South Korea
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
    • South Africa
    • North Africa
    • Central Africa

9. Competitive Landscape

• Gilead Sciences
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Merck & Co
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Johnson & Johnson
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hoffmann-La Roche AG
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Boehringer Ingelheim
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Achillion Pharmaceuticals
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us